Dr. Pedro Luiz Serrano Uson Junior

Oncologista · Mais sobre as especializações

São Paulo 1 endereço

Número de registro: CRM SP 148243 RQE Nº: 97475

Informações de contato

Experiência

Médico Oncologista com atuação no Hospital Israelita Albert Einstein, especialização na Mayo Clinic, nos Estados Unidos, na área de tumores gastrointestinais. Atua no Programa de Medicina de Precisão do Hospital Israelita Albert Einstein, liderando as iniciativas em pesquisa básica e clínica. Foco em medicina de precisão e personalização genômica do tratamento oncológico. Mais de 70 artigos científicos publicados em periódicos internacionais.
mais Sobre mim

Sobre mim

Médico Oncologista com atuação no Hospital Israelita Albert Einstein, especialização na Mayo Clinic, nos Estados Unidos, na área de tumores gastrointestinais. Atua no Programa de Medicina de Precisão do Hospital Israelita Albert Einstein, liderando as iniciativas em pesquisa básica e clínica. Foco em medicina de precisão e personalização genômica do tratamento oncológico. Mais de 70 artigos científicos publicados em periódicos internacionais.

Principais doenças tratadas

Experiência

Doctor
Pedro Luiz Serrano Uson Junior

Oncologista

Experiências profissionais

  • Mayo Clinic Cancer Center

Formação

  • Faculdade de Medicina do ABC
  • Hospital Israelita Albert Einstein

Doenças tratadas

Mostrar mais detalhes

Publicações

  • Título Citado por Ano Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome NJ Samadder, D Riegert-Johnson, L Boardman, D Rhodes, M Wick, ... JAMA oncology 7 (2), 230-237 249 2021 Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ... JAMA oncology, e204930-e204930 187 2020 The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ... Annals of Oncology 33 (12), 1269-1283 78 2022 Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study PLS Uson Jr, D Riegert-Johnson, L Boardman, J Kisiel, L Mountjoy, ... Clinical Gastroenterology and Hepatology 20 (3), e508-e528 71 2022 Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center BL Prado, DBD Gomes, PLS Usón Júnior, P Taranto, MS França, D Eiger, ... BMC Palliative Care 17, 1-7 54 2018 Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study PLS Uson Jr, NJ Samadder, D Riegert-Johnson, L Boardman, MJ Borad, ... Clinical and translational gastroenterology 12 (10), e00414 34 2021 Immune checkpoint inhibitors as therapy to down-stage hepatocellular carcinoma prior to liver transplantation NN Katariya, BC Lizaola-Mayo, DM Chascsa, E Giorgakis, BA Aqel, ... Cancers 14 (9), 2056 33 2022 A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma DH Ahn, PLS Uson Junior, P Masci, H Kosiorek, TR Halfdanarson, ... Investigational new drugs 40 (1), 134-141 30 2022 Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma G Botrus, H Kosirorek, MB Sonbol, Y Kusne, PLSU Junior, MJ Borad, ... The oncologist 27 2021 Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer PLSU Junior, ET Rother, FC Maluf, DDG Bugano Clinical Colorectal Cancer 17 (3), 187-197 25 2018 Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer MFC Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F Journal of Gastrointestinal Cancer 49 (4), 481-486 25* 2017 Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy MS França, PLS Usón, YPPV Antunes, BL Prado, CC Donnarumma, ... Einstein (Sao Paulo) 13 (2), 221-225 25* 2015 Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials PLSU Junior, DD e Silva, NM de Castro, E da Silva Victor, ET Rother, ... ESMO open 8 (1), 100771 24 2023 The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies PLS Usón, FDAS Tolentino, VM Santos, ET Rother, FC Maluf PloS One 15 (3), e0230060 24 2020 Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered PLS Usón Junior, MS França, HV Rodrigues, ALV Macedo, A Goldenberg, ... Einstein (Sao Paulo) 13, 347-351 22* 2015 Increasing stress to induce apoptosis in pancreatic cancer via the unfolded protein response (UPR) G Botrus, RM Miller, PLS Uson Junior, G Kannan, H Han, DD Von Hoff International journal of molecular sciences 24 (1), 577 20 2022 Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond PLS Uson Junior, MJ Borad Expert Opinion on Investigational Drugs 31 (1), 125-131 20 2022 Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival PLS Uson Junior, ESD Dias, NM de Castro, E da Silva Victor, ET Rother, ... A systematic review and meta-analysis of randomized controlled trials. ESMO … 18 2023 Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives M Zugman, G Botrus, RC Pestana, PLS Uson Junior Frontiers in Oncology 12, 860453 18 2022 Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data PLS Usón, DDG Bugano, MS França, YPPV Antunes, P Taranto, ... International Journal of Gynecologic Cancer 27 (2) 18 2017 Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis PLS Uson Junior, L Carvalho, MLC Fernandes, G Botrus, ... Scientific Reports 12 (1), 13592 17 2022 Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer Cancer Chemotherapy and Pharmacology 8, 10 17* 2020 Incidental findings in reduction mammoplasty specimens in patients with no prior history of breast cancer. An analysis of 783 specimens PLS Usón Junior, D Callegaro Filho, DDG Bugano, FC Geyer, ... Pathology & Oncology Research 24, 95-99 17 2018 Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy PLSU Junior, U Majeed, G Botrus, MB Sonbol, D Ahn, J Starr, J Jones, ... JCO Precision Oncology 15 2022 Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival Frontiers in Oncology 11 (794009), 1-9 14* 2022 Germline cancer susceptibility gene testing in unselected patients with hepatobiliary cancers: A multi-center prospective study Cancer Prevention Research 14* 2021 Timing of palliative care access and outcomes of advanced cancer patients referred to an inpatient palliative care consultation team in Brazil L Taniwaki, PLSU Junior, PMR de Souza, BL Prado Palliative & Supportive Care 17 (4), 425-430 14 2019 Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer PLSUJ Vladimir Galvão de Aguiar, Vanderlei Segatelli, Antônio Luís de ... Future Oncology 14 2019 The role of systemic therapy in resectable colorectal liver metastases: systematic review and network meta-analysis MB Sonbol, R Siddiqi, PLS Uson Jr, S Pathak, B Firwana, G Botrus, ... The oncologist 27 (12), 1034-1040 13 2022 Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the first global prostate cancer consensus conference for developing countries (PCCCDC) FC Maluf, FMT Pereira, PL Serrano Uson Jr, DA Bastos, ... JCO Global Oncology 7, 550-558 13 2021 Treatment of localized and locally advanced, high-risk prostate cancer: A report from the First Prostate Cancer Consensus Conference for Developing Countries R Khauli, R Ferrigno, G Guimarães, M Bulbulan, PLS Uson Junior, ... JCO Global Oncology 7, 530-537 12 2021 Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma PLSU Junior, AJ Liu, MB Sonbol, MJ Borad, TS Bekaii-Saab Chinese clinical oncology 10 (1), 11-11 12 2021 Advances in the treatment of biliary tract cancers PLSU Junior, J Bogenberger, MJ Borad Current Opinion in Gastroenterology 36 (2), 85-89 12 2020 Combination immunotherapy for hepatocellular carcinoma: where are we currently? PLSU Junior, BM Nagalo, DH Ahn, T Bekaii-Saab, MJ Borad Seminars in liver disease 41 (02), 136-141 11 2021 Body composition impact on survival and toxicity of treatment in pancreatic cancer: cross-sectional pilot study APN Barrère, SMF Piovacari, PLS Uson Junior, RC Gansl, AZ Pereira, ... Arquivos de Gastroenterologia, 1-5 11 2020 Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors PLS Uson Junior, VM Santos, DDG Bugano, ES Victor, ET Rother, ... Scientific Reports 9 (1), 15806 11 2019 Germline cancer testing in unselected patients with gastric and esophageal cancers: a multi-center prospective study PLS Uson Jr, KL Kunze, MA Golafshar, G Botrus, D Riegert-Johnson, ... Digestive diseases and sciences 67 (11), 5107-5115 10 2022 Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers BM Nagalo, Y Zhou, EJ Loeuillard, C Dumbauld, O Barro, NM Elliott, ... Hepatology 77 (6), 1943-1957 9 2023 Universal genetic testing vs. Guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program JC Jones, MA Golafshar, TW Coston, R Rao, E Wysokinska, E Johnson, ... Cureus 15 (4) 8 2023 FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations PLS Uson Junior, TT DeLeon, JM Bogenberger, RK Pai, HE Kosiorek, ... Digestive diseases and sciences, 1-9 7 2022 Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers M Arora, JM Bogenberger, AM Abdelrahman, J Yonkus, R Alva‐Ruiz, ... Hepatology 75 (1), 43-58 7 2022 Impact of Pathology Review for Decision Therapy in Localized Prostate Cancer P USON, O SMALETZ, R MACARENCO, F NUNES CLINICAL MEDICINE INSIGHTS: PATHOLOGY 7 2017 Dias E Silva D, de Castro NM, et al PLS Uson Junior Does neoadjuvant treatment in resectable pancreatic cancer improve overall … 7 Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications LA Kankeu Fonkoua, PL Serrano Uson Junior, K Mody, A Mahipal, ... Expert opinion on therapeutic targets 26 (1), 79-92 6 2022 Clinical Course, genetic, and immunohistochemical characterization of solid pseudopapillary tumor of the pancreas (Frantz tumors) in a Brazilian Cohort FT Tostes, PFDC de Carvalho, RLC Araújo, RC Ribeiro, ... Genes 13 (10), 1809 5 2022 Immunotherapy in biliary tract cancers: Current evidence and future perspectives PLSU Junior, RLC Araujo World Journal of Gastrointestinal Oncology 14 (8), 1446 5 2022 RECOMMENDATIONS FOR THE PREVENTION, SCREENING, DIAGNOSIS, STAGING, AND MANAGEMENT OF CERVICAL CANCER IN AREAS WITH LIMITED RESOURCES: REPORT FROM THE INTERNATIONAL … FC Maluf, G Dal Molin, A Melo, E Paulino, D Racy, R Ferrigno, ... Frontiers in Oncology, 4404 5 2022 Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. PLS USÓN JUNIOR, DDG BUGANO, F MOURA, RS CARVALHO, ... Journal of B.U.O.N. 5* 2018 Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier? PL Serrano Uson Junior, T Bekaii-Saab Immunotherapy 15 (7), 531-540 4 2023 Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond PLSU Junior, MJ Borad Seminars in liver disease 43 (02), 218-225 4 2023 Response to abemaciclib and Immunotherapy Rechallenge with nivolumab and ipilimumab in a heavily pretreated TMB-H metastatic squamous cell lung cancer with CDKN2A mutation … D Dias e Silva, GB Borba, JR Beal, G Botrus, A Osawa, SEA Araújo, ... International Journal of Molecular Sciences 24 (4), 4209 4 2023 RECOMMENDATIONS FOR THE TREATMENT OF VULVAR CANCER IN SETTINGS WITH LIMITED RESOURCES: REPORT FROM THE INTERNATIONAL GYNECOLOGICAL CANCER SOCIETY CONSENSUS MEETING F Maluf, G Zibetti, E Paulino, A Melo, D Racy, R Ferrigno, ... Frontiers in Oncology, 4909 4 2022 Consensus on the treatment and follow-up for the nonmetastatic castration-resistant prostate cancer: a report from the first prostate cancer consensus conference for developing … FMT Pereira, AG Silva, ALA Dettino, APG Cardoso, AD Sasse, AG Kann, ... JCO Global Oncology 7, 545-549 4 2021 Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases RLC Araujo, LG Fonseca, RO Silva, MM Linhares, PLSU Junior Hepatobiliary Surgery and Nutrition 13 (2), 273 3 2023 Establishing recurrence indicators and stratifying pancreatic ductal adenocarcinoma based on routine laboratory exams. Is it time to incorporate these parameters in daily … PLSU Junior, VM Santos, IL Souza, G Schvartsman, FC Maluf Journal of BU ON.: official journal of the Balkan Union of Oncology 25 (1 … 3 2020 Novel precision therapies for cholangiocarcinoma: An overview of clinical trials PLS Uson Junior, J Bearss, HM Babiker, MJ Borad Expert Opinion on Investigational Drugs 32 (1), 69-75 2 2023 Systemic therapy and sequencing options in advanced hepatocellular carcinoma: A Systematic Review and Network Meta-analysis., 2020, 6, p. e204930 MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ... DOI: https://doi. org/10.1001/jamaoncol 2 2020 Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Sci Rep 9 (1): 15806 PLS Uson Junior, VM Santos, DDG Bugano, E VictorRother, FC Maluf 2 2019 Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. JCO Glob Oncol … R Khauli, R Ferrigno, G Guimarães, M Bulbulan, PLS Uson Junior, ... 2 Spontaneous regression of advanced hepatocellular carcinoma following COVID-19 infection and vaccination: a case report and review of literature C Eslinger, PLS Uson Jr, BM Nagalo, MJ Borad Journal of Gastrointestinal Oncology 15 (4), 1933 1 2024 Clinical utility of ivosidenib in the treatment of IDH1-mutant cholangiocarcinoma: Evidence to date PLS Uson Junior, MJ Borad Cancer Management and Research, 1025-1031 1 2023 APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients FN Aslam, TA Loveday, PLSU Junior, M Truty, R Smoot, T Bekaii-Saab, ... Annals of Gastroenterology 37 (1), 95 1 2023 Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib G Botrus, D Roe, GS Jameson, PLSU Junior, RL Korn, L Caldwell, ... Biomedicines 10 (11), 2705 1 2022 Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments DPD Armentano, MR Monteiro, PN Aguiar Jr, JS Tsukamoto, RB Pio, ... einstein (São Paulo) 20, eAO6985 1 2022 Recent advances in understanding cholangiocarcinoma PLS Uson Junior, M Arora, J Bogenberger, MJ Borad Faculty Reviews 9 (15), 1-5 1 2020 Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy NHY Pedro Luiz Serrano Usón Junior, Jairo Wagner, Marcus Vinicius de Nigro ... Sage Open Medical Case Reports 1 2019 Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma DDE Silva, M Borad, PLSU Junior World Journal of Gastrointestinal Oncology 16 (12), 4766 2024 Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma? N Centrone, PLSU Junior World Journal of Gastrointestinal Oncology 16 (12), 4753 2024 Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis M Mariussi, MG Ruelas, LC de Oliveira Lima, FF Leite, MJS Cunha, ... 2024 Are preoperative inflammatory and nutritional markers important for the prognosis of patients with peritoneal metastasis of colorectal cancer? I Sforzin, M Borad, PLSU Junior World Journal of Gastrointestinal Oncology 16 (11), 4522 2024 Disparities in esophageal cancer care: a population-based study F Tustumi, RY Eri, KW Wende, ET Nakamura, PLSU Junior, DJ Szor Journal of Gastrointestinal Surgery 28 (10), 1674-1681 2024 Adjuvant treatment in resected biliary cancers: fluoropyrimidines on the spotlight PLSU Junior, MJ Borad Translational Cancer Research 13 (9), 4510 2024 Clear cell sarcoma of the pancreas, an unusual cancer with unusual metastatic site or unusual primary site? JC Moreno, PLSU Junior World Journal of Clinical Cases 12 (25), 5653 2024 Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer PLSU Junior, ALS Nagy, IWR Dias, MB de Rezende, R Pestana, ... Journal of Gastrointestinal Oncology 15 (4), 1820 2024 Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing JPB Cassoli, Í Fernandes, L Carvalho, M Fernandes, AF Centrone, ... Current Issues in Molecular Biology 46 (8), 7976-7985 2024 Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study NM Castro, F Moura, AL Hada, D Garcia, ES Victor, G Schvartsman, ... einstein (São Paulo) 22, eAO0575 2024 133P Molecular profile and actionability of sarcomas with next-generation sequencing: Insights from a single institution in Brazil M Zugman, M Fernandes, L de Lima, M Teixeira, T Xavier, I Dias, U Junior, ... ESMO Open 9 2024 Act Local, Think Global: IR and Its Role in Immuno-Oncology in Hepatocellular Carcinoma PLSU Junior, T Bekaii-Saab Journal of Vascular and Interventional Radiology 35 (2), 173-177 2024 An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer H Mahadevia, PLS Uson Junior, J Wang, M Borad, H Babiker Expert Opinion on Pharmacotherapy 25 (1), 79-90 2024 A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma PLS Uson, J Bearss, HM Babiker, M Borad Expert Opinion on Drug Safety 22 (8), 637-641 2023 Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts. B Heald, SM Nielsen, I Ekpoh, D Alexander, R Pai, MA Golafshar, ... Journal of Clinical Oncology 41 (16_suppl), e22537-e22537 2023 Timing of specialized palliative care integration and its impact on quality of end-of-life care indicators among Latin American cancer patients. D Dias e Silva, V Melo Ferreira, DB Swerts, GN Eleoterio, LIT Takahashi, ... Journal of Clinical Oncology 41 (16_suppl), e24168-e24168 2023 Does neoadjuvant treatment in resectable pancreatic cancer improve disease outcomes? Systematic review and metanalysis of randomized controlled trials. D Dias e Silva, NM Castro, ES Victor, ET Rother, SEA Araújo, F Moura, ... Journal of Clinical Oncology 41 (4_suppl), 704-704 2023 Utility of AST to platelet ratio index (APRI) score in predicting post-surgical outcomes in patients with cholangiocarcinoma. F Aslam, T Loveday, PLS Uson Junior, MJ Borad Journal of Clinical Oncology 41 (4_suppl), 502-502 2023 Prognostic impact of Sarcopenia on clinical outcomes in advanced hepatocellular carcinoma (HCC) treated with systemic therapy G Botrus, PLSU Junior, H Kosiorek, M Akce, I Chang, Z Mesbah, ... Cancer Research 82 (12_Supplement), 6274-6274 2022 Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments. DP Domigues Armentano, M Ribeiro Monteiro, PN Aguiar Jr, ... Einstein (16794508) 20 2022 Targeting Fgfr Pathway: Precision Medicine for Biliary Cancer and beyond PLSU Junior, M Borad Seminars in liver disease 2022 1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer PLSU Junior, G Botrus, J Yin, H Dada, L Drusbosky, U Majeed, D Ahn, ... Annals of Oncology 32, S1093-S1094 2021 A Pilot Study of Ponatinib in Patients With FGFR-Altered Advanced Cholangiocarcinoma DH Ahn, PLSU Junior, P Masci, H Kosiorek, TR Halfdanarson, K Mody, ... 2021 Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy. U Majeed, PLS Uson Junior, J Yin, MB Sonbol, DH Ahn, TS Bekaii-Saab, ... Journal of Clinical Oncology 39 (15_suppl), 4079-4079 2021 Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer. G Botrus, PLS Uson Junior, P Raman, A Kaufman, HE Kosiorek, ... Journal of Clinical Oncology 39 (15_suppl), 4130-4130 2021 Abstract PD10-05: Universal genetic testing in breast cancer patients: A multi-center prospective study 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San … 2021 Adenocarcinoma de Pâncreas GE de Cuidado 2021 Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States PLSU Junior, D Ahn, MB Sonbol, T Bekaii-Saab, MJ Borad Hepatobiliary Surgery and Nutrition 9 (4), 501 2020 Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer A Goldenberg, RC Gansl, FC Maluf, PL Serrano 2019 Gamma-Glutamyl Transferase (GGT) as an Early Predictor of Better Progression-Free Survival in Well-Differentiated Gastroenteropancreatic Neuro-Endocrine Tumors (GEP-NET) in … DP Armentano, M Monteiro, P Aguiar, R Brandao, J Tsukamoto, R Pio, ... NEUROENDOCRINOLOGY 108, 177-177 2019 LAPAROSCOPIC TIPS AND TRICKS TO TREAT CHYLOUS ASCITES AFTER OPTIMAL LAPAROSCOPIC OVARIAN CANCER DEBULKING: A DEMONSTRATIVE VIDEO R Moretti Marques, GB Barbosa, RG Garcia, LR Ferraz, VA Bezerra, ... INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 28, 117-117
Agendar consulta

Serviços e preços

  • Primeira consulta cancerologia

Consultório

Pedro Luiz Serrano Uson Junior
Hospital Israelita Albert Einstein

Av Albert Einstein 627, Morumbi, São Paulo 05652-000

Ampliar o mapa abre num novo separador

Disponibilidade

Este especialista não oferece agendamento online neste endereço

Detalhes do endereço

Pesquisa de serviços relacionados

Serviços

Hospital Israelita Albert Einstein

Planos de saúde não aceitos

Este especialista só aceita pacientes particulares. Você pode pagar particular para marcar, ou encontrar outro especialista que aceite o seu plano de saúde.

Opiniões em breve

Envie a primeira opinião

Você já passou por consulta com Dr. Pedro Luiz Serrano Uson Junior? Conte aqui como foi. Outros pacientes vão te agradecer por ajudá-los a escolher o melhor especialista.

Enviar opinião

Perguntas frequentes

Oncologistas próximos
Doenças mais tratadas
Convênios médicos mais populares

É necessário efetuar o pagamento da consulta

Seu especialista pede que você efetue o pagamento da consulta. Para reagendar, você pode pagar antecipadamente ou entrar em contato diretamente com seu especialista.
As minhas visitas Efetuar pagamento